PUTRAJAYA, April 7 — The Ministry of Health (MOH) has agreed to grant additional indication approval for the product Evusheld 100 milligrammes per millimetre (mg/ml) Solution for Injection (Tixagevimab 100 mg/ml and Cilgavimab 100 mg/ml) manufactured by Astrazeneca AB of Sweden.

KUALA LUMPUR, June 8 — The Health Ministry (MOH) will start administering treatments with the monoclonal antibody drugs Tixagevimab and Cilgavimab (Evusheld) in the near future to ensure that high-risk groups continue to be protected from Covid-19 infection.

KUALA LUMPUR, May 13 — The Ministry of Health (MOH) has agreed to grant conditional registration approval for the product Evusheld 100 milligrammes per millimetre (mg/ml) Solution For Injection (Tixagevimab 100 mg/ml and Cilgavimab 100 mg/ml) manufactured by AstraZeneca AB of Sweden.